Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Narrowly Misses Nasdaq Delisting Warning

NEW YORK, Sept. 20 (GenomeWeb News) - Sequenom narrowly missed receiving a delisting warning from the Nasdaq exchange after is share price closed above $1 last Friday.


Shares in the San Diegogenotyping and gene-expression tool company closed at $1.13 Sept. 17. If the stock closed below $1, as it had for the previous 29 trading days, Sequenom would have received a letter from the Nasdaq exchange warning it of its failure to meet minimum trading requirements---the first step in what could have become delisting proceedings.


The exchange typically sends its listed companies such letters if their shares trade below $1 for 30 consecutive trading days.

"Certainly we're making every effort to get the price above $1: increasing newsflow, meeting with the investment community to find some new buyers for stock, and fill some of the holes that have been created," a company spokesperson told GenomeWeb News last week. "That's the main plan, at the moment, to build demand for the stock."


Before Sept. 17, Sequenom shares last traded on or above $1 on Aug. 5. Had its shares not met the minimum trading criteria, the Nasdaq would have issued a letter giving Sequenom 90 days in which to comply. If the company failed to raise the price above $1 for 90 days after receiving the letter, and maintain a closing price above the threshold for 10 trading days, it would have been downgraded to the Nasdaq small-capitalization market.


After that step, Sequenom would have to go through the same process, starting with closing above $1 in a 30-day period. Should it fail the second cycle, the company risks the delisting of its stock to the over-the-counter market.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more